Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of single-agent regorafenib in
the first line treatment of frail and/or unfit for polychemotherapy patients with metastatic
colorectal cancer (mCRC)
Phase:
Phase 2
Details
Lead Sponsor:
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)